Mersana Therapeutics, a biopharmaceutical company developing its Fleximer® antibody-drug conjugate (ADC) platform and pipeline of small molecule Fleximer conjugates, today announced its participation in the upcoming 13th Annual Meeting of the Massachusetts Biotechnology Council.

Timothy B. Lowinger, Ph.D., Chief Scientific Officer, is scheduled to participate in the Antibody Drug Conjugates panel on Friday, March 15, 2013, at 8:45 a.m. at the Royal Sonesta Hotel in Cambridge.

About Mersana

Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Utilizing its proprietary conjugation technology, which is comprised of the Fleximer® polymer and a broad array of customizable linker chemistries, Mersana is developing its next-generation antibody-drug conjugate (ADC) platform with superior properties not found with other ADC technologies. Mersana is currently working with a number of top Pharma companies to develop next generation Fleximer-ADCs and most recently announced a $270 million collaboration with Endo Pharmaceuticals in March, 2012. The company is also advancing its own pipeline of next-generation drugs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications. 

Media Contacts:

 MacDougall Biomedical Communications
 Kari Watson
 781-235-3060
 kwatson@macbiocom.com